Business Context and Reporting Period
Company: GRI Bio, Inc. (GRI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: GRI is a clinical-stage biopharmaceutical company developing therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells for idiopathic pulmonary fibrosis (IPF). A secondary candidate, GRI-0803, targets autoimmune disorders like lupus. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,046) | $(1,887) |
| Net Loss Per Share (Basic & Diluted) | $(5.80) | $(101.05) |
| Cash and Cash Equivalents (End of Period) | $3,281 | $4,091 |
| Cash Used in Operating Activities | $(1,736) | $(2,203) |
| Total Assets | $4,042 | $5,739 |
| Total Liabilities | $2,837 | $1,707 |
| Stockholders' Equity | $1,205 | $4,032 |
| Accumulated Deficit | $(42,786) | $(33,420) |
Operating Expenses: Total operating expenses were $3.05 million for Q1 2025, comprised of $1.64 million in Research and Development (R&D) and $1.41 million in General and Administrative (G&A) costs.
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss increased by approximately 61% year-over-year, driven by a $0.7 million increase in R&D expenses related to the GRI-0621 registration development program and a $0.4 million increase in G&A expenses due to higher personnel and professional fees.
- Capital Structure Changes: The company executed a 1-for-17 reverse stock split on February 21, 2025, reducing outstanding shares to approximately 525,358. This action was taken to regain compliance with Nasdaq's Minimum Bid Price Rule.
- Warrant Repricing: In October 2024, the company repriced certain Series B warrants, resulting in a deemed dividend of $1.53 million recorded in equity. This transaction is not reflected in the Q1 2025 income statement but impacts equity balances.
- Stock-Based Compensation: Stock-based compensation expense rose significantly to $220,000 in Q1 2025 compared to $37,000 in Q1 2024, following the grant of 21,128 stock options.
Guidance, Outlook, and Risks
Liquidity and Going Concern: As of March 31, 2025, the company held $3.28 million in cash. Management states there is substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Current cash is projected to fund operations only through the third quarter of 2025. Additional financing is required to continue operations.
Recent Financing (Subsequent Event): On April 1, 2025, the company closed a public offering (April 2025 Offering) raising gross proceeds of $5.0 million through the sale of common stock and pre-funded warrants. This transaction, combined with subsequent ATM sales, has increased stockholders' equity above $2.5 million as of the filing date.
Clinical Outlook:
- GRI-0621: Enrollment for the Phase 2a biomarker study for IPF is ongoing. Interim data is expected in Q2 2025, with topline results in Q3 2025.
- GRI-0803: Development is currently limited pending additional funding. An IND application for a Phase 1a/1b trial targeting lupus is expected in 2025.
Internal Controls: Management identified a material weakness in internal controls related to the inaccurate computation of a non-cash deemed dividend associated with the warrant repricing transaction. Remediation plans are underway.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.0 million raised in the April 2025 offering to extend the operating runway beyond Q3 2025.
- Dilution Impact: Assess the dilutive effect of the April 2025 Offering, which included significant issuance of pre-funded warrants and Series E warrants.
- Clinical Milestones: Monitor the Q2 2025 interim data release for the GRI-0621 Phase 2a trial, as success is critical for future funding.
- Internal Control Remediation: Confirm the status of remediation for the material weakness regarding warrant accounting to ensure future financial reporting reliability.
- ATM Capacity: Note the company's ability to sell up to $1.67 million in additional shares under its updated At-The-Market (ATM) facility as of May 2025.